New York, NY -- (SBWIRE) -- 01/24/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: VIVUS, Inc (NASDAQ:VVUS), Endeavour Silver Corp (NYSE:EXK), Achillion Pharmaceuticals, Inc (NASDAQ:ACHN), Education Realty Trust, Inc (NYSE:EDR)
VIVUS, Inc (NASDAQ:VVUS) showed a volume of 2.29 million shares by the end of last trade whereas the average volume of the stock remained 1.90 million shares. The stock opened the session at $8.39 but then moved to $8.31. At that price, the stock showed a negative performance of -0.72%. VIVUS, Inc. is a biopharmaceutical company. It commercializes and develops therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health. Its drug, Qsymia (phentermine and topiramate extended-release) was approved by the the United States Food and Drug Administration (FDA) for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 or greater (obese),
Will VVUS Get Buyers Even After The Recent Rally? Find Out Here
Endeavour Silver Corp (NYSE:EXK) opened the session at $4.44 and closed the session at $4.50. The stock showed a positive performance of 4.17% in previous trading session. Endeavour Silver Corp. (Endeavour) is engaged in the evaluation, acquisition, exploration, development and exploitation of silver mining properties in Mexico and in exploration in Chile. The Company’s producing mines include Guanacevi mine,
For How Long EXK will fight for Profitability? Read This Trend Analysis report
Achillion Pharmaceuticals, Inc (NASDAQ:ACHN) opened the session at $4.04 and closed the session at $3.94. The stock showed a negative performance of -3.43% in previous trading session. The beta of the stock remained 0.37. Achillion Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases. The Company is engaged in the development of antivirals for the treatment of chronic hepatitis C infection (HCV), and the development of antibacterials for the treatment of resistant bacterial infections.
Why Should Investors Buy ACHN After the Recent Fall? Just Go Here and Find Out
Education Realty Trust, Inc (NYSE:EDR) the stock decreased -0.33% and finished the session at $9.17. Traded with volume of 2.18 million shares in the prior session and the average volume of the stock remained 951,478.00 shares. The beta of the stock remained 1.02. Education Realty Trust, Inc. (the Trust) is a self-managed and self-advised real estate investment trust (REIT). The Company develops, acquires, owns and manages collegiate housing communities located near university campuses.
Will EDR Get Buyers Even After The Recent Rally? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)